European Journal Of Haematology · 2021 · 11 citations · 31 references
MedicineOncologyPathologyMolecular OncologyMolecular PathologyNeoplasiaCancer Molecular PathologyCirculating Tumor Dna AnalysisLymphoid TumorsMalignant NeoplasmsNext-generation Sequencing In OncologyTumor ImmunopathologyCirculating Tumor Dna SequencingCirculating Tumor Dna TestingClinical Next-generation SequencingClonal Mutation AnalysisMedian AgeMutationSomatic Genomic AlterationsTumor Mutation Detection
OBJECTIVES: Castleman disease (CD) is a heterogeneous group of disorders involving systemic inflammation and lymphoproliferation. Recently, clonal mutations have been identified in unicentric CD (UCD) and idiopathic multicentric CD (iMCD), suggesting a potential underlying neoplastic process. METHODS: Patients with UCD or iMCD with next generation sequencing (NGS) data on tissue DNA and/or circulating tumor DNA (ctDNA) were included. RESULTS: Five patients were included, 4 with iMCD and 1 with UCD. Four patients (80%) were women; median age was 40 years. Three of five patients (60%) had ≥1 clonal mutation detected on biopsy among the genes included in the panel. One patient with iMCD had a 14q32-1p35 rearrangement and a der(1)dup(1)(q42q21)del(1)(q42) (1q21 being IL-6R locus) on karyotype. This patient also had a NF1 K2459fs alteration on ctDNA (0.3%). Another patient with iMCD had a KDM5C Q836* mutation, and one patient with UCD had a TNS3-ALK fusion but no ALK expression by immunohistochemistry. CONCLUSIONS: We report 4 novel somatic alterations found in patients with UCD or iMCD. The 1q21 locus contains IL-6R, and duplication of this locus may increase IL-6 expression. These findings suggest that a clonal process may be responsible for the inflammatory phenotype in some patients with UCD and iMCD.
31
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
Kazuyuki Yoshizaki, Tadashi Matsuda, Naoki Nishimoto et al. · Blood · 1989 · 904 citations